Q32 Bio
QTTB · Nasdaq · United States
Share price · QTTB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when QTTB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Jul 2026+90.7%
- 27 May 2026+81.2%
- 26 May 2026+22.2%
Nothing announced by QTTB that day or the session before.
- 20 Apr 2026+13.7%
Nothing announced by QTTB that day or the session before.
- 30 Mar 2026-18.6%
- Day beforeQ32 Bio: Entry into a material agreement
- 19 Mar 2026+14.8%
Nothing announced by QTTB that day or the session before.
- 11 Mar 2026+15.4%
- 10 Mar 2026+17.5%
- 1 Dec 2025+74.4%
Share of unusual movement by asset
For each asset, the share of QTTB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IL-7 receptor alphaMonoclonal antibody | Atopic DermatitisAlopecia Areata |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.2M | $290M | $8.9M-$4.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $4.3M | $106M | $8.9M-$3.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $3.2M | $51M | $7.6M-$6.3M operating cash flow | report ↗ |
| 2025-Q3 | — | $3.6M | $49M | $7.4M-$4.2M operating cash flow | report ↗ |
| 2025-Q2 | — | $5.2M | $55M | $9.5M-$11M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.1M | $65M | $11M-$12M operating cash flow | report ↗ |
| 2024-Q3 | — | $14M | $89M+ $0 short-term inv. | $18M-$20M operating cash flow | report ↗ |
| 2024-Q2 | — | $13M | $98M+ $10.0M short-term inv. | $17M-$22M operating cash flow | report ↗ |
| 2024-Q1 | — | $9.8M | $116M+ $20M short-term inv. | —-$15M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $18M | $29M+ $74M short-term inv. | $33M-$25M operating cash flow | report ↗ |
| 2023-Q2 | $0.3M | $23M | $77M+ $50M short-term inv. | $35M-$24M operating cash flow | report ↗ |
| 2023-Q1 | $0.8M | $20M | $39M+ $111M short-term inv. | $29M-$26M operating cash flow | report ↗ |
| 2022-Q3 | $0.8M | $26M | $43M+ $158M short-term inv. | $34M-$25M operating cash flow | report ↗ |
| 2022-Q2 | $0.8M | $21M | $176M+ $49M short-term inv. | $29M-$31M operating cash flow | report ↗ |
| 2022-Q1 | $0.8M | $24M | $248M+ $8.0M short-term inv. | —-$31M operating cash flow | report ↗ |
| 2021-Q3 | $1.7M | $24M | $96M+ $92M short-term inv. | $31M-$25M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $19M | $48M | —-$34M operating cash flow | report ↗ |
Q32 Bio reported collaboration arrangement revenue of $53.7M for 2025 versus none in 2024; total revenue was not separately disclosed. R&D expense was $19.16M, down 60.2% YoY, and cash and cash equivalents were $48.3M as of December 31, 2025. Full-year net income was $29.82M, driven by non-cash collaboration revenue and the ADX-097 sale, compared with a net loss of $47.7M in 2024.
The company completed enrollment in Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata, increasing the trial to 33 patients, with 36-week topline data expected mid-2026 and an open-label extension from Part A ongoing. It also completed a $10.5M registered direct offering in February 2026, sold the Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12M in upfront and near-term milestone payments, with up to $592M in potential milestones plus tiered royalties, and terminated all remaining obligations to Amgen. Management expects cash, RDO proceeds, and guaranteed ADX-097 milestones to fund operations into Q4 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $48M | $78M+ $0 short-term inv. | $12M-$68M operating cash flow | report ↗ |
| 2023-FY | $1.2M | $62M | $39M+ $0 short-term inv. | $28M-$96M operating cash flow | report ↗ |
| 2022-FY | $3.2M | $98M | $34M+ $141M short-term inv. | $1.3M-$114M operating cash flow | report ↗ |
| 2021-FY | $34M | $93M | $108M+ $47M short-term inv. | $24M-$110M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 4 purchases ($30.0M), 11 sales ($505K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-06 | Kalowski Lee · CFO and President | Open-market sale | 1,301 | $8.32 | $11K | Form 4 |
| 2026-10-06 | Violette Shelia M. · Chief Scientific Officer | Open-market sale | 917 | $8.32 | $8K | Form 4 |
| 2026-10-06 | Morrison Jodie Pope · director, CEO | Open-market sale | 3,221 | $8.32 | $27K | Form 4 |
| 2026-08-25 | Violette Shelia M. · Chief Scientific Officer | Open-market sale | 2,798 | $16.56 | $46K | Form 4 |
| 2026-08-25 | Kalowski Lee · CFO and President | Open-market sale | 3,972 | $16.56 | $66K | Form 4 |
| 2026-08-25 | Morrison Jodie Pope · director, CEO | Open-market sale | 9,845 | $16.56 | $163K | Form 4 |
| 2026-07-16 | Kalowski Lee · CFO and President | Award / grant | 53,250 | — | — | Form 4 |
| 2026-07-16 | Morrison Jodie Pope · director, CEO | Award / grant | 132,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 53 reporting institutions held 9.4M shares ($59.3M, 31.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 2,252,987 | $14.5M |
| 2 | Atlas Venture Life Science Advisors, LLC | 2,092,106 | $13.4M |
| 3 | Opaleye Management Inc. | 1,256,228 | $8.1M |
| 4 | Carlyle Group Inc. | 1,102,741 | $7.1M |
| 5 | ARCH Venture Management, LLC | 320,482 | $2.1M |
| 6 | ACORN CAPITAL ADVISORS, LLC | 315,052 | $2.0M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 306,401 | $2.0M |
| 8 | MACKENZIE FINANCIAL CORP | 246,304 | $1.6M |
| 9 | Sanofi | 244,083 | $1.6M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 206,915 | $1.3M |
| 11 | MONIMUS CAPITAL MANAGEMENT, LP | 134,310 | $862K |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 118,152 | $759K |
| 13 | Pfizer Inc | 101,618 | $737K |
| 14 | BlackRock, Inc. | 86,147 | $553K |
| 15 | JANE STREET GROUP, LLC | 65,599 | $421K |